Recurrent digital ulcers are a manifestation of vascular disease in patients with systemic sclerosis leading to severe pain, impaired function and tissue loss. Treatment with the endothelin receptor antagonist, bosentan, has recently been shown to be of benefit in patients with severe Raynaud phenomenon and in the prevention and treatment of digital ulcers in systemic sclerosis.1^–4 To our knowledge, there are no reports in the English literature on the use of bosentan on non-digital …